FDA Clearance Tracker · P940015-S012
SYNVISC-ONE
Last checked: Nov 20, 2026Latest source record: Feb 26, 2009 (this decision)Source: openFDAMethods & limitations
Decided
Feb 26, 2009
Approved
Time to decision
618 days
Received Jun 19, 2007. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Panel Track
Device class
Class III
The decision
- FDA number
- P940015-S012
- Device name
- SYNVISC-ONE
- Applicant
- Sanofi Genzyme Corp.
- Applicant location
- Cambridge, MA
- Received
- Jun 19, 2007
- Decided
- Feb 26, 2009
- Decision
- Approved
- Supplement type
- Panel Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P940015
Device type
- Device type
- Acid, hyaluronic, intraarticular (MOZ)
- Device class
- Class III
- Specialty
- Orthopedic Surgery
FDA's approval statement
As written in FDA's record.
APPROVAL FOR THE SYNVISC-ONE. THE DEVICE IS INDICATED FOR THE TREATMENT OF PAIN IN OSTEOARTHRITIS OF THE KNEE IN PATIENTS WHO HAVE FILED TO RESPOND ADEQUATELY TO CONSERVATIVE NON-PHARMACOLOGIC THERAPY AND SIMPLE ANALGESICS, E.G., ACETAMINOPHEN.
Source documents
Other decisions for Sanofi Genzyme Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.